• news.cision.com/
  • Gradientech AB/
  • Gradientech previews QuickMIC™, an ultra-rapid IVD system for antibiotic susceptibility testing (AST) at ECCMID 2019
English

Gradientech previews QuickMIC™, an ultra-rapid IVD system for antibiotic susceptibility testing (AST) at ECCMID 2019

Report this content

Uppsala, Sweden, April 12, 2019. Gradientech is displaying its QuickMIC™ system for the first time at ECCMID, the world’s premier clinical microbiology & infectious diseases conference, taking place in Amsterdam on April 13-16. During the ECCMID conference, the public will have the opportunity to preview the QuickMIC system and meet the experts behind its development.

QuickMIC is a precision system for ultra-rapid antibiotic susceptibility testing, designed to provide personalized treatment options for sepsis patients in record time. Currently, there is an urgent need for rapid solutions that can diagnose which antibiotics a sepsis patient should be treated with.

“Every hour counts, and the sooner you can find out which antibiotic is the propriate to treat with, the higher chance for the patient to survive” says Sara Thorslund, CEO of Gradientech.

“We foresee that our IVD QuickMIC system, which is in final development, will make a real difference by determining phenotypic AST directly from positive blood culture of patients with sepsis in as short as 2 hours”, explains Sara.

By reducing inappropriate inpatient use of antibiotics, Gradientech strongly believes that QuickMIC will lead to increased survival rates, reduced healthcare costs and lower antibiotic resistance.

Discover QuickMIC at ECCMID 2019, RAI, Amsterdam

  •  Booth 1.73, Exhibition Hall 1, 13-16 April
  •  Mini-Oral ePoster Session, 15 April, 14:18pm

Malmberg, C. Rapid and high-throughput phenotypic AST directly from positive blood cultures with very high precision MIC values.

For further information, please contact:
Sara Thorslund, PhD, CEO Gradientech
Tel: +46 736 29 35 80
sara.thorslund@gradientech.se

About Gradientech
Gradientech is a diagnostics company developing the in vitro diagnostic QuickMIC® system, a new platform for antibiotic susceptibility testing based on phenotypic bacterial growth analysis. The system is expected to become the most rapid solution for determining appropriate antibiotic treatment of sepsis patients. Rapid antibiotic susceptibility testing is vital for increasing sepsis patient survival, reducing healthcare costs and lowering the spread of antibiotic resistance. www.gradientech.se

Subscribe

Media

Media